At a glance
ClinicalIndex Comparison RecordN/ACompleted· 20 enrolled
Drug / intervention
Creatine Monohydratedietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Creatine to Augment Bioenergetics in Alzheimer's
In Brief
A clinical study evaluating Creatine Monohydrate for Alzheimer's Disease. Completed, enrolled 20 participants across 1 site.
Detailed Summary
By doing this study, researchers hope to see if creatine monohydrate is a helpful treatment for people with Alzheimer's disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease
CountriesUnited States
CollaboratorsAlzheimer's Association
Timeline
N/ACompletedFinished
2023202420252026
First PostedMay 2022
Enrollment StartDec 2022
Primary CompletionMay 2024
TodayJul 2026
First PostedMay 20, 2022
Enrollment StartDec 12, 2022
Primary CompletionMay 14, 2024
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 4.1 years ago
Interventions
Creatine Monohydratedietary
Participants will take 20 grams of creatine monohydrate daily for 8 weeks.The 20 grams will be divided into two equal 10 gram doses that will be stirred into a beverage. One 10 gram dose will be taken in the morning and the other 10 gram dose in evening.